What was the overall market valuation for the prostate cancer-treatment market in 2024?

The overall market valuation for the prostate cancer-treatment market was $415.55 Million in 2024. Read More

What is the projected market valuation for 2035?

The projected market valuation for 2035 is $725.9 Million. Read More

What is the expected CAGR for the prostate cancer-treatment market during the forecast period 2025 - 2035?

The expected CAGR for the prostate cancer-treatment market during the forecast period 2025 - 2035 is 5.2%. Read More

Which companies are considered key players in the prostate cancer-treatment market?

Key players in the prostate cancer-treatment market include Astellas Pharma, Bayer, Johnson & Johnson, Pfizer, Merck & Co., Novartis, Sanofi, Ipsen, and Eli Lilly and Company. Read More

What were the revenue ranges for surgery in the prostate cancer-treatment market?

The revenue range for surgery in the prostate cancer-treatment market was between $83.33 Million and $150.0 Million. Read More

How does the revenue for radiation therapy compare to other treatment types?

The revenue for radiation therapy ranged from $124.44 Million to $220.0 Million, indicating a strong performance compared to other treatment types. Read More

What is the revenue range for the intravenous administration route?

The revenue range for the intravenous administration route was between $124.44 Million and $220.0 Million. Read More

Which end user segment had the highest revenue in 2024?

In 2024, the hospitals segment had the highest revenue, ranging from $150.0 Million to $270.0 Million. Read More

What is the revenue range for metastatic disease stage treatments?

The revenue range for metastatic disease stage treatments was between $145.55 Million and $245.9 Million. Read More

What are the projected trends for the prostate cancer-treatment market in the coming years?

The prostate cancer-treatment market is expected to grow steadily, with a projected valuation of $725.9 Million by 2035. Read More

France Prostate Cancer Treatment Market

France Prostate Cancer Treatment Market Research Report By Treatment Type (Surgery, Radiation Therapy, Hormonal Therapy, Chemotherapy, Immunotherapy), By Administration Route (Oral, Injection, Intravenous, Topical), By End Users (Hospitals, Clinics, Homecare, Research Institutions) and By Disease Stage (Localized, Locally Advanced, Metastatic) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

5.2%

2024 Market Size

$ 415.55 Million

2035 Market Size

$ 725.9 Million

Healthcare ● Updated February 2026 Report ID: MRFR/HC/50966-HCR | Pages: 200 | Author: Satyendra Maurya, Garvit Vyas

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Type (USD Million)
  1. 4.1.1 Surgery
  2. 4.1.2 Radiation Therapy
  3. 4.1.3 Hormonal Therapy
  4. 4.1.4 Chemotherapy
  5. 4.1.5 Immunotherapy
2. 4.2 Construction, BY Administration Route (USD Million)
  1. 4.2.1 Oral
  2. 4.2.2 Injection
  3. 4.2.3 Intravenous
  4. 4.2.4 Topical
3. 4.3 Construction, BY End Users (USD Million)
  1. 4.3.1 Hospitals
  2. 4.3.2 Clinics
  3. 4.3.3 Homecare
  4. 4.3.4 Research Institutions
4. 4.4 Construction, BY Disease Stage (USD Million)
  1. 4.4.1 Localized
  2. 4.4.2 Locally Advanced
  3. 4.4.3 Metastatic
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Astellas Pharma (JP)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bayer (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Johnson & Johnson (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Pfizer (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Merck & Co. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Novartis (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Sanofi (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Ipsen (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Eli Lilly and Company (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 FRANCE MARKET ANALYSIS BY TYPE
3. 6.3 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
4. 6.4 FRANCE MARKET ANALYSIS BY END USERS
5. 6.5 FRANCE MARKET ANALYSIS BY DISEASE STAGE
6. 6.6 KEY BUYING CRITERIA OF CONSTRUCTION
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CONSTRUCTION
9. 6.9 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
11. 6.11 SUPPLY / VALUE CHAIN: CONSTRUCTION
12. 6.12 CONSTRUCTION, BY TYPE, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CONSTRUCTION, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
15. 6.15 CONSTRUCTION, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Million)
16. 6.16 CONSTRUCTION, BY END USERS, 2024 (% SHARE)
17. 6.17 CONSTRUCTION, BY END USERS, 2024 TO 2035 (USD Million)
18. 6.18 CONSTRUCTION, BY DISEASE STAGE, 2024 (% SHARE)
19. 6.19 CONSTRUCTION, BY DISEASE STAGE, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY ADMINISTRATION ROUTE, 2025-2035 (USD Million)
  3. 7.2.3 BY END USERS, 2025-2035 (USD Million)
  4. 7.2.4 BY DISEASE STAGE, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

France Prostate Cancer Treatment Market Segmentation

France Prostate Cancer Treatment Market By Type (USD Million, 2025-2035)

Surgery
Radiation Therapy
Hormonal Therapy
Chemotherapy
Immunotherapy

France Prostate Cancer Treatment Market By Administration Route (USD Million, 2025-2035)

Oral
Injection
Intravenous
Topical

France Prostate Cancer Treatment Market By End Users (USD Million, 2025-2035)

Hospitals
Clinics
Homecare
Research Institutions

France Prostate Cancer Treatment Market By Disease Stage (USD Million, 2025-2035)

Localized
Locally Advanced
Metastatic

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”